FiercePharmaAsia—Sun’s key Halol plant, Eisai’s new Alzheimer’s center, Takeda-Shire opponents

15th June 2018 Uncategorised 0

Sun Pharma finally frees its key plant for the U.S. market from FDA restrictions; Eisai will open up a new genetics-driven drug discovery site focused on Alzheimer’s disease; opponents to Takeda’s $62 billion deal for Shire look to rally enough support to call off the transaction; and more.

More: FiercePharmaAsia—Sun’s key Halol plant, Eisai’s new Alzheimer’s center, Takeda-Shire opponents
Source: fierce